Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Trial Identifier: 215253
Sponsor: GlaxoSmithKline
Collaborator:
Not applicable
Start Date: November 2021
Primary Completion Date: December 2022
Study Completion Date: March 2023
Condition: Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Alberta Edmonton, Alberta, Canada, T6G 1C3
Canada, Ontario London, Ontario, Canada, N6A 5R9
Canada, Ontario London, Ontario, Canada, N6H 5L5
United States, Arkansas North Little Rock, Arkansas, United States, 72117
United States, Florida Miami, Florida, United States, 33155
United States, Florida Tampa, Florida, United States, 33613
United States, Michigan Troy, Michigan, United States, 48084
United States, Oklahoma Oklahoma City, Oklahoma, United States, 73118
United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19103
United States, Texas San Antonio, Texas, United States, 78218
United States, Texas Sugar Land, Texas, United States, 77479